As described in the clinical website: https://clinicaltrials.gov/ct2/show/NCT03712280 They're still in phase 2a for studying pharmacodynamics/safety/pharmacokinetics of oral administration MNK6106. If the clinical data comming out in the upcoming October is good, they're definitely going to start Phase 3 trial for oral MNK6106, and for this we'll receive $0.52/share as soon as the very first patient enrolled for the trial.
Below is the 3 milestone payments: 1). $0.52/share if the first patient is enrolled in a Phase 3 for oral trial MNK6106 2). $0.34/share if the first patient is enrolled in a Phase 3 for IV trial MNK6105. 3) $1.72/share if the combined sales of MNK6105 & MNK6106 worldwide exceed $500 million before 2029